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Sulfur amino acid metabolism in cystinuria: A biochemical and clinical
study of patients. Sulfur amino acid metabolism was studied in 26
homozygotic cystinuric patients, some of whom received D-penicil-
lamine, 2-mercaptopropionyiglycine or N-acetylcysteine treatments in
order to evaluate signs of cyst(e)ine deficiency. Decreased leukocyte
glutathione and taurine levels, plasma cyst(e)ine and taurine concen-
trations and urinary inorganic sulfate, taurine, mercaptolactate and
thiosulfate outputs were found in cystinuric patients, probably re-
flecting intracellular cyst(e)ine deficiency. An increased mercaptoace-
tate-cysteine mixed disulfide output was found, probably a result of a
poor tubular reabsorption of this compound, as well as for cystine.
Normal retinal function was recorded in all patients. During drug
treatments, the excretion of most of the sulfur compounds in cystinurics
was as those found in controls, probably reflecting an increased
mobilization of cysteine. N-acetylcysteine treatment increased the
excretion of cyst(e)ine and can thus not be recommended as stone
preventive therapy in cystinuria.
Since it became known that the type of urine concrement
originally described by Wollaston [1] is almost entirely com-
posed of cystine, the majority of work on cystinuria has been
directed at finding ways to decrease the urinary excretion of
cystine. Thereby the frequency of stone formation [21, and also
secondary renal complications [2, 3] could be reduced.
Despite the relative frequency of cystinuria [2] and the
characteristic and reliable diagnostic criteria for the disease [2,
3], only limited clinical data have accumulated on potential
"metabolic disorders" related to cystinuria. Coexistence of
mental illness or retardation have been reported [4—1 lb possi-
bly related to an impaired lysine transport over the blood-brain
barrier. Clinical conditions including short stature [12], hyper-
uricemia [13—15], and malabsorption syndrome [161 have also
been described.
Although cystinuric patients experience marked losses of
cystine in the urine and stools, it is generally thought that the
subjects do not develop cyst(e)ine deficiency [2]. Thus, cystinu-
ric subjects are generally healthy in appearance and have
essentially normal plasma methionine and cyst(e)ine levels [2,
17, 18]. That pronounced cyst(e)ine deficiency does not develop
is probably explained by that normal gastrointestinal and renal
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absorptions of cysteine [19], cysteine containing dipeptides and
methionine [2] are found.
A reduced plasma cyst(e)ine level has, however, been ob-
served in some cystinuric patients [19], and decreased excre-
tions of inorganic sulfate [18] and taurine [20], the two major
metabolites of cysteine in humans, have also been reported.
The latter results emphasize the importance of further meta-
bolic studies on sulfur amino acid metabolism in cystinuria.
The aim of the present investigation was to study whether
biochemical signs of sulfur amino acid, that is, cyst(e)ine,
deficiency develops in homozygotic cystinuric patients, by
determination of the urinary excretions and plasma concentra-
tions of sulfur amino acids and the urinary output of their main
degradation products [21]. Leukocyte sulfur amino acid (SAA)
and glutathione concentrations were also determined [22]. The
results were compared with corresponding data obtained from
cystinuric patients receiving treatment with 2-mercaptopropio-
nylglycine (2-MPG) [20] or D-penicillamine (PA) [2], and to
healthy age-matched subjects on a similar well balanced diet
[21, 22]. Data on two cystinurics receiving N-acetylcysteine
(NAC) were also included, since NAC has been advocated as a
potent solvolytic agent of renal cystine stones in cystinuria [23,
24]. However, because there was a substantial and sustained
increased output of cyst(e)ine by both of our patients receiving
NAC, this treatment had to be abandoned. An extensive study
on the therapeutic effect of NAC treatment in cystinuria could
thus not be performed. Since recent data indicate that adequate
tissue concentrations of taurine [25, 26] and glutathione [27] are
probably essential for maintenance of normal retinal function,
an ophthalmologic examination, including electroretinograms
(ERG), was recorded in the six subjects with most pronounced
biochemical evidence of glutathione and taurine deficiencies.
Methods
Materials
The subjects were outpatients who had normal and stable
weight and who consumed a well balanced diet. The food intake
was regulated by protocol to ensure a caloric intake of at least
2800 kcal per day. The patients did not restrict their intake of
foods rich in proteins or sulfur amino acids. Blood samples
were taken between 9 and 11 a.m. after an overnight fast to
avoid any circadian variation in free glutathione concentration.
Urine samples were collected from two consecutive days with
thymol-isopropanol as the preservative in each subject. A more
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Table 1. Clinical and laboratory data on the patients
.Disease Stone Creatinine
span on X- U-protein Clear- Complicating
Index Sex Age years Treatment Lithotomi ray 0.3 glliter ASAT ALAT ALP Serum ance disease
Group HF F 17 1 Fluids + + — 0.39 0.23 2.19 82 88 —NS GL M 64 37 Fluids, Bicarb 8 g + (+) — 0.37 0.34 2.15 107 62 —
HN F 26 3 Fluids, Bicarb 15 g — — — 0.25 0.27 1.73 62 145
SN M 49 34 Fluids, Bicarb 3 g — — — 0.25 0.27 2.23 83 89 —
BP F 48 23 Fluids, Bicarb 6 g — + — 0.34 0.46 2.58 60 90 —
Group SA F 66 45 Fluids, PA 1.0 g + — — 0.36 0.26 2.42 116 60 Hypertonia
PA IN F 40 17 Fluids, PA l.Og + — — 0.13 0.14 1.88 65 117 —
IN F 36 15 Fluids, PA 0.75 g -- — — 0.41 0,38 1.68 111 85 —
AN M 32 14 Fluids, PA 2.5 g + (+) — 0.27 0.19 1.89 107 111 —
AS M 42 7 Fluids, PA 1.0 g + — — 0.64 0.43 2.73 103 98 —
Group RA M 23 17 Fluids, MPG 2.5 g + — — 0.47 0.53 0.99 67 121 —
2-MPG HA M 34 9 Fluids, MPG 1.5 g + — — 0.31 0.54 3.63 84 109 —
LE F 27 15 Fluids, MPG 1.5 g + — — 0.31 0.40 2.38 85 99 —
IG M 56 36 Fluids, MPG 0.5 g — — — 0.32 0.44 1.97 89 117 —
MH F 24 II Fluids, MPG 0,75 g + — — 0.26 0.23 1.24 72 126 —
EH M 66 19 Fluids, MPG 0.25 g — — — 0.28 0.50 3.34 75 122 Psoriasis
HH M 71 1 Fluids, MPG 0.5 g — (+) — 0.24 0.19 3.46 122 67 —
JH M 41 21 Fluids, MPG 1.75 g + — — 0.41 0.81 3.31 108 95 Psoriasis
P-AH M 43 18 Fluids, MPG 1.0 g + + — 0.32 0.55 2.21 125 93 —
EJ F 25 4 Fluids, MPG 1.5 g + — — 0.49 0.65 1.59 65 120 —
VL F 29 11 Fluids, MPG 1.5 g + + — 0.34 0.18 1.89 79 88 —
SN F 50 16 Fluids, MPG 1.5 g + — — 0.40 0.33 1,01 80 75 —
Reference values are: ASAT, 0.72 skat/liter; ALAT, 0.72 katIliter; ALP, 5.0 akat/1iter.
a No specific (drug) treatmentb Serum creatinine 60 to 120 smol/liter; creatinine clearance 55 to 95 mI/mm/I .72 m2 BSA
detailed clinical and biochemical description of the patients is
given in Table 1. All patients treated with PA or 2-MPG had
received the drug for at least one year, whereas the NAC
treatment was given for 6 and 12 weeks, respectively.
One patient (S.A.) in the PA group had hypertonia for which
he was successfully treated with metoprolol (Seloken) at 100
mg daily. One patient (U-M.T.) in the NAC group had well
controlled hypertonia and hypothyreosis for which she received
continuous medications with 100 ing metoprolol and 0.1 mg
levothyroxine (Levaxine®). She also had well regulated, diet-
controlled adult-type diabetes mellitus and exhibited low grade
proteinuria of the glomerular type. No patients exhibited clini-
cal or laboratory signs of urinary tract infection.
The control group consisted of 10 adults (24 to 35 years of
age) on a similar well-balanced diet. Their food intake was not
controlled but for caloric intake (minimum 2800 kcal per day).
Their intake of protein was indirectly estimated through a
determination of their excretion of nitrogen, sulfur, and inor-
ganic sulfate [21, 281 and urea (Discussion). The excretion
values were based on samples from two different days, which
was identical to the procedure in our cystinuric patients.
All patients had received full information about the aims and
plan of the investigation prior to the study, which were ap-
proved by the Ethical Committee of the hospital (Linkoping).
Methods
Analytical procedures for determination of sulfur containing
compounds were identical to those previously used [21, 22],
apart from thiosulfate which was measured by a more specific
method using HPLC and electrochemical detection [29). The
quantitation of cystine output designated cyst(e)ine, included
both cystine excreted as such and any cysteine oxidized to
cystine during urine collection. A modification of the original
procedure [30] for mercaptolactate, mercaptoacetate and N-
acetylcysteine had to be introduced [31], due to the huge extra
load of cystine, MPG and PA found in our patients. Briefly, a 20
ml ion-exchange column (AG5OWX8, H-form) was introduced
prior to the Hg-absorption step to eliminate cystine and PA, and
the capacity of the Hg-column was expanded to 3.0 ml to retain
the extra load of acid thiols, that is, 2-MPG found in the 2-MPG
treated patients. All of the urine chromatograms from 2-MPG
patients showed a high early peak with a retention time similar
to that of mercaptoacetate [311. Addition of synthetic mercap-
toacetate produced, however, a second peak with a slightly (2
mm) more prolonged retention time. Identification by GC-MS
showed a mass spectrum identical to that 2-mercaptopropion-
ate, probably generated by degradation of 2-MPG. Owing to
co-chromatography of MPG and NAC in both the original [30]
and modified procedures [31], it was not possible to quantitate
the NAC output in 2-MPG treated subjects.
Drug interference were found also during amino acid analy-
ses. For penicillamine, its symmetric and mixed (with cysteine)
disulfide forms run with similar retention times to those of
cystathionine and methionine, respectively. This problem was
solved by re-running the same sample after treatment with
dithiothreitol. This procedure does not affect methionine or
cystathionine. Furthermore, the reduced form of 2-MPG had an
identical retention time with taurine. The peak plasma concen-
tration of 2-MPG in healthy adults after an oral intake of 500 mg
of the compound was 50 to 200 molIliter [32], thus of the same
order of magnitude as the normal plasma taurine level. How-
ever, a falsely increased "taurine" output in 2-MPG treated
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Table 2. Urinary excretion of mam sulfur compounds
Reference
group
Cystinuric patients
NS 2-MPG PA NA
Total sulfura 13.8 0.47 10.5 0.92 12.9 0.94 12.8 0.77 15.2;17.8
Inorganic sulfatea 11.0 0.42 5.60 0,63b 7.34 0.63 7.40 0.38c 8.17;l0.l
Ester sulfatea 1.16 0.09 1.18 0.15 1.20 0.09 1.38 0.23 l.56;l.38
Total sulfate%
Total sulfur 89.0 1.40 62.7 2.5b 66.2 3.4 68.6 3.2 67 .4 ;64 .5
Non-sulfate sulfura 1.22 0.17 3.90 0,22b 4.26 0.74 4.00 0.74 4.92;6.32
Non-sulfate sulfur 1.04 0.15 0.91 0.18 1.30 0.36 1.28 0.16 1.69 1.67
a [21], mmol/24 hr/rn2 body surface area (mean sEM)b Statistically significant with respect to reference group, P < 0.05
Statistically significant with respect to NS group, P < 0.05'Minus cyst(e)ine output
subjects was probably not present, since the "oxidative milieu"
in urine strongly favors the formation of disulfides, including
the symmetric and mixed (with cysteine) disulfides forms of
2-MPG. The mixed disulfide form of 2-MPG yields a broad peak
in the aspartate region of the chromatogram. If the reduced
2-MPG form interferes with plasma and intracellular (leuko-
cyte) taurine analyses remains, however, to be more thoroughly
evaluated. The present low absorbance (440/570 nm) ratios for
plasma and leukocyte taurine peaks found were identical to that
of authentic taurine, whereas reduced 2-MPG shows a higher
absorbance ratio (unpublished observations). Thus, a major
contribution of MPG to the measured taurine levels in our
2-MPG patients seems highly unlikely.
Urinary total sulfur outputs of 2-MPG and PA patients were
corrected for the amounts excreted of the two drugs. PA output
was determined from the ordinary amino acid chromatogram,
whereas 2-MPG was analyzed separately [33]. Excretion values
for all compounds were calculated as a mean value of two
sample determinations from two consecutive days for each
subject.
Statistical analyses were based on the two way ANOVA to
determine whether cystinuria per se affects SAA metabolism,
or whether the PA or the MPG treatment alters SAA metabo-
lism in cystinuric patients. Differences obtained between con-
trols and cystinurics without drug treatment, or between the
latter group and PA or 2-MPG treated cystinurics were individ-
ually compared using the Tukey test. Only P values 0.05 were
regarded as significant. Results for the NAC-treated patients
were not statistically evaluated because of the limited number
of subjects investigated.
Results
A normal excretion for total sulfur was found in all patients,
except patients receiving NAC who had an increased output of
total sulfur (Table 2). All patients, except for those receiving
NAC, showed a significantly decreased output of inorganic
sulfate (Table 2). A normal sulfate ester excretion was regis-
tered in all groups (Table 2). Significantly reduced total sulfate
(inorganic + ester sulfate) to total sulfur ratios were calculated
in all groups, expressing an increased output of non-sulfate
sulfur compounds in all patients (Table 2). However, after
subtraction of the cyst(e)ine excretion from the non-sulfate
sulfur output in the cystinuric patients, a normalization of the
non-sulfate sulfur output was found. Notably, in NAC treated
patients an increased non-sulfate sulfur excretion was found
even after taking their cyst(e)ine outputs into account.
A significantly decreased excretion of methionine was found
in cystinuric patients, whereas patients with PA treatment had
an increased output of methionine (Table 3). Plasma and
leukocyte methionine concentrations showed large, but insig-
nificant, variations, except in PA treated patients who had a
raised intracellular level of the compound. A normal cystathio-
nine output was found in cystinuric patients, except during PA
treatment when an increased excretion of the compound oc-
curred (Table 3). By definition, a significantly increased cyst(e)
me excretion was found in all cystinuric patients, although it
was significantly less pronounced in 2-MPG and PA treated
patients (Table 3). However, the total cyst(e)ine output in
2-MPG and PA patients, also including any cysteine excreted as
mixed disulfides with 2-MPG or PA, were 3020 204 and 2720
150 (mean sEM) imol/24 hr/m2 BSA, respectively, which
were not significantly different from that found in NS treated
patients. In contrast, all patients had significantly reduced
plasma cystine concentrations. NAC treated patients had low-
normal plasma levels of cystine. A significantly decreased
taurine output was found in all cystinuric patients, except PA
treated subjects, who had a normal taurine excretion (Table 3).
Decreased plasma and leukocyte taurine concentrations were
found in NS treated patients. During 2-MPG or PA treatment
the plasma and leukocyte levels of taurine increased, although
it became significant only for PA treated patients.
A significantly decreased mercaptolactate output was found
in cystinurics, and it was not significantly affected by the MPG
or the PA treatment (Table 4). During NAC treatment the
mercaptolactate output increased. In contrast, cystinurics had a
significantly increased excretion of mercaptoacetate and it was
not significantly affected by any of the treatments (Table 4).
Increased outputs of N-acetylcysteine were found in PA and
NAC treated patients, whereas cystinurics without treatment
had a normal excretion of this compound (Table 4). In 2-MPG
patients, N-acetylcysteine output was not measurable due to an
analytical interference by 2-MPG (Methods). A decreased thio-
sulfate output was found in cystinuric patients, whereas treat-
ment with 2-MPG increased the excretion of thiosulfate (Table
4). However, due to the large variation in thiosulfate outputs
they did not become statistically significant. Notably, a patient
treated with PA excreted 257 tmol/24 hr/rn2 BSA of thiosulfate.
Decreased free and total leukocyte glutathione concentra-
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Table 3. Urinary excretion and plasma and leukocyte concentrations of sulfur amino acids
Reference Cystinuric patients
group NS 2-MPG PA NAC
Methiomne
Urinea 12.6 1.0 5.88 0,42d 6.85 0.34 13.1 0,37e 6.70;12.9
Plasmab 22.0 3.0 20.0 1.8 19.2 2.7 19.4 2.5 18.0;24.0
Leukocytec 18.0 1.0 16.8 4.6 23.9 3.4 33•3 94C 21;25
Cysathionine
Urinea 13.3 1.8 15.2 3.9 16.9 2.5 35.2 2.8e 14.8;19.l
1/2 Cystine
Urinea 92.3 12.0 2960 370" 1870 339 1720 358 4950;3730
Plasma" 900 6.0 54.3 7.61 52.3 8.2 30.2 47 82.0;72.0
Taurine
Urinea 419 69 26.3 9,9' 127 66 335 58 423;294
Plasma" 72.0 6.0 38.4 5,3" 50.4 5.7 54.8 33 59.0;47.0
Leukocytec 19.0 0,11 16.0 0.86" 19.4 1.5 25.3 1.7 19.6;17.9
a [21], tmol/24 hr/rn2 body surface area (mean SEM)b [22], molIliter, corresponding to values previously published [58], in [221 concentrations were erroneously given in mol/liter
[22], nmol per 106 (taurine), io (methionine) cells
d p < 0.05 to reference group
P < 0.05 to NS group
Table 4. Urinary excretion of minor sulfur metabolities
Reference Cystinuric patients
group NS 2-MPG PA NAC
Mercaptolactatea 18.3 1.5 2.73 079b 3.52 1.0 3.10 1.1 5.37;8,83
Mercaptoacetatea 5.09 0.27 19.7 074b 19.4 5.0 21.8 2.9 17.3;18.0
Nacetylcysteinea 11.3 0.85 13.7 2.1 ND 16.5 2.0 97.4;189
Thiosulfatea 13.1 1.7 3.20 0.95" 15.8 4.0 55.7 50 10.5;8.70
ND, not determined (see Methods). If the patient with a thiosulfate output of 267 mo1I24 hr/rn2 BSA was deleted in the calculations, the PA
treated patients mean thiosulfate output became 5.46 1.67 tmo1J24 hr/rn2 BSA.
a [21] rno1/24 hr/rn2 body surface area (mean SEM)b P < 0.05 to reference group
Table 5. Leukocyte free, mixed protein-bound, and total gluthathione concentrations
Refrence
group
Cystinuric patients
NS 2-MPG PA NAC
Free glutathionea 19.8 0.61 13.5 1.2" 16.1 0.95c 23.0 1.1 l5.9;l8.7
Mixed protein-bound 3.81 0.48 3.82 0.69 3.42 0.42 6.67 1.3 4.20;3.70
glutathionea
Total glutathionea 23.7 0.47 17.4 1.9" 19.6 0.94 29.7 l.5c 21.1;22.4
a [22], nmol per IO cells (mean sEal)
<0,05 to reference group
P < 0.05 to NS group
tions were found in cystinurics (Table 5). During PA or 2-MPG
treatment the free and total glutathione concentrations in-
creased. The mixed protein-bound forms of glutathione were
not significantly altered in cystinuria.
A general ophthalmological examination, including visual
fields and dark adaptations tests, did not reveal any abnormal-
ities in the six patients with most marked biochemical evidences
of taurine and glutathione depletions. ERG measurements in
the same patients did not show significant abnormalities with
respect to amplitude and implicite time for the a- and b-waves.
The c-wave was variable without any significant change (data
not shown).
Discussion
The excretion of total sulfur and inorganic sulfur reflect sulfur
amino acid intake [28] and reduced outputs are found during
fasting [211. In cystinurics, a voluntarily imposed dietary re-
striction of the intake of sulfur amino acids is at times observed
[2, 3] with the implication of decreasing the dietary load of
cyst(e)ine and thus limiting the chances of developing cystine
concrements. In this study, a low protein or sulfur amino acid
intake could not be substantiated, since normal urea (cystin-
urics 141 23, with PA 198 60, with 2-MPG 196 60, and
controls 180 25 (mean SD) mmolI24 hr/m2 BSA) and total
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sulfur outputs were found in all cystinurics. The low inorganic
sulfate output found in cystinurics probably reflect that less
amounts of sulfur amino acids are oxidized to inorganic sulfate
in cystinuric patients, and that increased amounts of sulfur
amino acids are being used for synthetic purposes, for example,
glutathione and protein synthesis, in cystinuria, due to the
limited availability of cyst(e)ine induced through the increased
losses of cystine with the urine and the stools. Furthermore,
increased inorganic sulfate outputs were noted during 2-MPG
and PA treatments without an altered diet, probably reflecting
an increased mobilization of cysteine, in part by disulfide
exchange. The cysteine thus mobilized is readily taken up by
cells including those of the intestine and renal tubules in
cystinurics [19]. During NAC treatment a normal inorganic
sulfate output was found, reflecting an efficient hydrolysis of
NAC to cyst(e)ine, which can be further oxidized to inorganic
sulfate.
As expected [2], the treatment with 2-MPG or PA markedly,
and to a similar extent, decreased the output of cyst(e)ine in
cystinurics. The total excretions of cyst(e)ine, however, also
including any cysteine excreted in the form of 2-MPG and PA
mixed disulfides, were not significantly reduced. In contrast,
NAC, like cysteine [34], increases the output of cyst(e)ine in
cystinurics. Furthermore, less than 5% of the total amounts of
NAC given were excreted unchanged, which supports a rapid
postabsortive deacylation of NAC with increased formation of
cysteine. This supports previous indications [23, 35] that NAC
does not seem to have a therapeutic role in preventing stone
formation in cystinuric patients, which has been suggested [24].
Our patients treated with PA showed biochemical signs of a
defect transsulfuration of methionine to serine [36], with de-
creased plasma levels of cystine, increased cystathionine out-
puts, and an accumulation of methionine in leukocytes. The
most plausible explanation to these results is that, vitamin B6,
in spite of supplementation, was limiting, since vitamin B6
deficiency is prone to develop in patients during treatment with
PA. Vitamin B6 deficiency results in a reduced cystathionase
activity of the transulfuration pathway with a decreased con-
version of methionine to cysteine.
Most human cells are without appreciable taurine synthesiz-
ing capacity, and are thus totally dependent on exogenous
supply or endogeneous, such as, from liver, translocation of the
compound. In fact, a significant cysteine sulfinate decarboxyl-
ase activity, an essential enzyme in taurine biosynthesis, has
only been demonstrated in liver and brain in humans [37].
Recent studies in rodents show that, apart from liver and brain,
the enzyme is also present in kidney, although the activity is
lower [38, 39]. Cysteine is the superior substrate for synthesis
of taurine [40], and a reduced urinary output of taurine is a sign
of cyst(e)ine deficiency in humans [41, 42]. As previously
reported for cystinurics, our patient had a low plasma level [43]
and a decreased urinary output [25, 44, 45] of taurine. In strong
support of a general intracellular shortage of taurine [44, 45],
our cystinurics also had reduced leukocyte concentrations of
taurine. As earlier indicated, we found that treatment with PA
[43] or 2-MPG [201 increases the urinary output of taurine in
cystinurics, although the effect of PA treatment was more
pronounced. Thus, the increased excretion of taurine during PA
or MPG treatment supports the hypothesis that these drugs
mobilize cysteine through disulfide exchange both from dietary
and endogeneous sources. Notably, in patients treated with PA
a decreased plasma level of cystine was found, indicating that
this pool of cysteine was also mobilized during the PA treat-
ment, although vitamin B6 deficiency could also have contrib-
uted to the decreased formation of cysteine, as earlier dis-
cussed. Untreated cystinurics, in contrast to healthy normal
subjects have a net uptake of taurine in the kidney [19],
indicating that the low levels of taurine presently found in
leukocytes in our cystinuric patients not receiving PA or 2-MPG
may be decreased even more in the kidney.
Unexpectedly, all cystinurics had decreased excretion of
mercaptolactate (mixed disulfide), whereas their excretion of
mercaptoacetate (mixed disulfide) was increased. Metaboli-
cally, these two transaminative metabolites of cysteine [46] are
usually positively correlated [21, 41, 47], and the finding of an
opposite excretion pattern in cystinurics was thus surprising. A
plausible, but not likely, explanation may refer to differences in
renal handling of these two disulfides in cystinurics. The
mercaptoacetate-cysteine mixed disulfide would thus be less
reabsorbed than the corresponding mercaptolactate-cysteine
mixed disulfide form as a result of the tubular transport defect
in cystinuria. This hypothesis has to be verified by determina-
tion of the plasma level and the renal clearances of the two
compounds in cystinurics. The sensitivity of the present
method [29, 30] was, however, not high enough (1 jsM) for this
purpose, since the plasma levels for mercaptolactate and mer-
captoacetate are in the 0.01 to 0.2 /SM range (unpublished
observations). More likely, the reduced output of mercaptolac-
tate in cystinurics reflects the cyst(e)ine shortage earlier dis-
cussed, since the mercaptolactate output increased during NAC
treatment when increased amounts of cysteine were generated.
N-acetylcysteine is to a large extent excreted as a mixed
disulfide with cysteine [29], and is as such likely to be affected
by the transport defect in cystinuria. Thus, the normal output of
NAC in cystinuric patients was not easily interpreted, since it
does not favor a renal handling of the NAC-cysteine mixed
disulfide in common with either the mercaptolactate- or the
mercaptoacetate-cysteine mixed disulfide. The result may re-
flect a neutralization effect of a combination of a decreased
availability of cysteine resulting in a reduced acetylation of
cysteine [21, 48] with a low NAC output, and a decreased
tubular absorption of the NAC-cysteine mixed disulfide, as a
result of the transport defect in the kidney with an increased
excretion of NAC. During treatment with NAC an increased
output of NAC was found, but the amounts excreted repre-
sented only 5% of the intake. The results shows that NAC is
rapidly metabolized in humans and cannot be recommended as
a therapeutic approach to reduce cystine output in cystinuric
patients.
Thiosulfate is thought mainly to be synthesized from cysteine
in the body [46], which seems to involve the anaerobic flora of
the gut [491. In cystinuria, a reduced intestinal absorption of
cystine is found [2, 19], and increased amounts of cystine
should then be presented to the gut flora for metabolism. In
cystinurics a low output of thiosulfate was found, which sup-
ports our claim of a cyst(e)ine shortage in cystinuric patients.
Furthermore, the decreased output of thiosulfate in NS treated
cystinurics indicate that cysteine but not cystine is effectively
utilized in the formation of thiosulfate by the gut bacteria [49].
Additionally, the results suggest that the cystine reducing
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capacity of the "gut" cannot be significant. In 2-MPG and PA
treated patients an increased thiosulfate output was found,
which supports the hypothesis of a cysteine mobilizing effect of
these drugs. However, PA is known, apart from its disulfide
reducing ability, to have a high affinity for certain metal ions,
such as copper and molybdene. The potential risk of inducing a
metal deficiency during PA treatment should thus always be
considered [2]. Molybdene is a known co-factor of sulfite
oxidase, which catalyzes the final step of cysteine oxidation of
sulfite to inorganic sulfate. In patients with molybdene defi-
ciency an accumulation of sulfite occurs. Since sulfite is toxic,
alternative pathways of sulfite detoxification are activated, with
the formation of sulfocysteine and thiosulfate [46, 50]. Conse-
quently, an increased output of thiosulfate in PA treated pa-
tients may not only reflect the cysteine mobilization effect of the
drug, but could also indicate a reduced sulfite oxidase activity,
that is, molybdene deficiency.
Glutathione serves as a major intracellular protective agent
against the toxicity produced by reactive oxygen species, as
H202 and lipidperoxides [51]. Glutathione has also been shown
to function as an intracellular reservoir of cysteine [52]. Thus,
the decreased concentrations of free and total leukocyte gluta-
thione found in our cystinurics supports our previous results of
limited cysteine availability in cystinuria. This hypothesis is
further strengthened by the observations that NAC (partially),
2-MPG (partially) and PA (completely) normalized the leuko-
cyte glutathione levels, probably through the increased mobili-
zation of cysteine.
The results obtained on cystinurics in the present investiga-
tion indicate a general shortage of cyst(e)ine in these patients, in
part characterized by a deficiency of taurine and glutathione. In
humans, a prolonged and severe deficiency of taurine [26] or
glutathione [27] may result in the development of abnormal
retinal functions. In our limited investigation on the most
severely depleted patients we did not find any convincing
evidence of retinal dysfunction, The degree of glutathione and
taurine deprivation found in our cystinurics were, however, not
as pronounced as those previously reported in patients with
retinal dysfunction [26, 271. Furthermore, the present technique
of measuring implicite time was not done by flicker fusion [26],
which may have decreased the sensitivity of the present instru-
ment. In conclusion, the results do not favor major retinal
defects of either the outer or inner portion of the retinal
membrane in patients with uncomplicated cystinuria.
The biochemical signs of cysteine deficiency found in
cystinurics were more or less corrected by the specific treat-
ments used. These results favors the opinion that PA and
2-MPG, in spite of being potentially toxic [2, 35], do not further
deteriorate the abnormal sulfur amino acid status, that is,
cyst(e)ine deficiency, found in cystinurics. On the contrary,
increased cysteine availability is found during treatments with
PA or 2-MPG. It must, however, be kept in mind that alter-
ations in leukocyte sulfur amino acid and glutathione concen-
trations may not always parallel the changes found in other
tissues [53, 54]. The effects of cystinuria on glutathione and
sulfur amino acid concentrations in kidney and intestinal cells
are in this context especially important to evaluate, since they
are the primary two issues affected by the membrane transport
defect in cystinuria, and are thus likely to be the tissues most
severely depleted of cysteine.
In spite of the absence of major clinical symptoms and retinal
defects in patients with cystinuria, the biochemical signs of
cysteine deficiency observed may prove important if the cysti-
nuria is complicated through additional illness known to affect
sulfur amino acid or glutathione metabolism [27, 41, 51, 55—57].
Nutritional manipulations per se, as through the use of vegetar-
ian diets which at times are advocated to decrease the sulfur
amino acid (that is, cyst(e)ine), load in cystinunes [2, 3] may
prove deleterious, since subjects using these regimens over an
extended period of time are prone to develop sulfur amino acid
and glutathione deficiencies 121, 22]. Finally, the present paper
describes changes in sulfur amino acid and glutathione metab-
olism during a partially uncontrolled nutritional intake and
should be interpreted likewise. Previous studies on sulfur amino
acid metabolism by the authors [21, 22, 41, 42, 46, 47, 49, 57]
and others [28, 40] indicate, however, that the differences
presently observed cannot be explained through subtle changes
in the intake of sulfur amino acids or proteins, since the
cystinuric patients had a normal output of total sulfur (low with
a sulfur amino acid-deficient diet) and a decreased excretion of
mercaptolactate (increased with a low protein and food intake).
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